Josh Arnold Investment Consultant LLC Takes $32.34 Million Position in Teleflex Incorporated $TFX

Josh Arnold Investment Consultant LLC purchased a new position in shares of Teleflex Incorporated (NYSE:TFX) during the 4th quarter, HoldingsChannel reports. The institutional investor purchased 265,000 shares of the medical technology company’s stock, valued at approximately $32,341,000. Teleflex accounts for about 17.7% of Josh Arnold Investment Consultant LLC’s investment portfolio, making the stock its 2nd biggest holding.

Other institutional investors have also added to or reduced their stakes in the company. Banque Cantonale Vaudoise lifted its position in shares of Teleflex by 82.5% during the 4th quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock worth $31,000 after buying an additional 113 shares in the last quarter. V Square Quantitative Management LLC bought a new position in Teleflex in the 4th quarter valued at $37,000. UMB Bank n.a. grew its position in shares of Teleflex by 57.1% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the medical technology company’s stock valued at $38,000 after purchasing an additional 113 shares in the last quarter. Sound Income Strategies LLC purchased a new position in shares of Teleflex during the fourth quarter worth about $45,000. Finally, Kestra Advisory Services LLC bought a new position in shares of Teleflex in the fourth quarter worth approximately $45,000. 95.62% of the stock is owned by institutional investors.

Teleflex Price Performance

TFX stock opened at $126.97 on Friday. Teleflex Incorporated has a 1 year low of $100.18 and a 1 year high of $139.67. The company has a market cap of $5.62 billion, a P/E ratio of -5.57, a PEG ratio of 0.93 and a beta of 0.82. The firm has a 50-day moving average of $129.54 and a 200 day moving average of $119.33. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.55 and a quick ratio of 2.03.

Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, May 7th. The medical technology company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $1.21 by $0.18. Teleflex had a positive return on equity of 13.29% and a negative net margin of 35.88%.The business had revenue of $548.30 million for the quarter, compared to analysts’ expectations of $536.91 million. During the same period in the previous year, the firm posted $1.44 EPS. The business’s revenue was up 32.3% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. On average, sell-side analysts forecast that Teleflex Incorporated will post 6.7 EPS for the current year.

Teleflex Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Monday, May 25th will be paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 1.1%. The ex-dividend date is Friday, May 22nd. Teleflex’s dividend payout ratio (DPR) is currently -5.96%.

Analyst Ratings Changes

Several brokerages have issued reports on TFX. Wells Fargo & Company lifted their target price on shares of Teleflex from $130.00 to $138.00 and gave the company an “equal weight” rating in a research report on Friday, May 8th. Piper Sandler upgraded shares of Teleflex from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $140.00 to $160.00 in a research report on Monday, June 8th. Wall Street Zen cut Teleflex from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings restated a “sell (d)” rating on shares of Teleflex in a research report on Friday, March 27th. Finally, Raymond James Financial restated an “outperform” rating and set a $150.00 price target on shares of Teleflex in a research report on Friday, May 8th. Four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $146.00.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.